Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

GSK collaborates closely with Canadian sites — such as hospitals and other health-care centres — to operationalize its trials ...

The top UN health official gave a sobering reality check as the Fourth Global High-Level Ministerial Meeting on Antimicrobial ...

The Indian government is setting up a centre for research and development to boost domestic manufacturing of renewable energy ...

Since 2022, all new units within the Houston Land Bank must be built to meet its accessibility standards. The organization ...

The state of New York is asking atomic energy developers and major power users to share information about their interest in ...

Lenovo said its hybrid AI strategy is “paying off” as the tech giant announced double-digit growth across its client device, ...

Ms Nkabala emphasised the importance of community involvement in research, citing the Kiteezi incident, where Makerere had ...

Can artificial intelligence-powered tools help enrich child development and learning? That question is the crux of a series ...

Comments about the CHIPS and Science Act by President-elect Donald Trump and U.S. House Speaker Mike Johnson before the ...

GE HealthCare's AI initiatives, including AI-powered imaging solutions and strategic partnerships, are led by its chief AI ...

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...